Moody Aldrich Partners LLC Sells 51,872 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Moody Aldrich Partners LLC decreased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 43.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,415 shares of the company’s stock after selling 51,872 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Protagonist Therapeutics were worth $2,602,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Pacer Advisors Inc. lifted its holdings in Protagonist Therapeutics by 8.2% in the fourth quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company’s stock valued at $72,432,000 after acquiring an additional 142,376 shares during the period. KBC Group NV raised its stake in shares of Protagonist Therapeutics by 54.4% in the fourth quarter. KBC Group NV now owns 2,093 shares of the company’s stock worth $81,000 after buying an additional 737 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Protagonist Therapeutics by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock worth $121,000 after buying an additional 295 shares during the period. Contravisory Investment Management Inc. bought a new position in shares of Protagonist Therapeutics in the fourth quarter worth about $251,000. Finally, Assenagon Asset Management S.A. bought a new position in shares of Protagonist Therapeutics in the fourth quarter worth about $2,016,000. Institutional investors own 98.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on PTGX shares. StockNews.com downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Wedbush reaffirmed an “outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, December 10th. The Goldman Sachs Group started coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They issued a “neutral” rating and a $47.00 price objective on the stock. Finally, BMO Capital Markets started coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $62.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $53.78.

Protagonist Therapeutics Price Performance

NASDAQ PTGX opened at $37.99 on Wednesday. The stock has a market capitalization of $2.26 billion, a PE ratio of 14.28 and a beta of 2.23. The business has a 50 day simple moving average of $39.96 and a two-hundred day simple moving average of $41.84. Protagonist Therapeutics, Inc. has a 1-year low of $24.22 and a 1-year high of $48.89.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.05. The business had revenue of $4.68 million during the quarter, compared to analysts’ expectations of $4.50 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. On average, analysts anticipate that Protagonist Therapeutics, Inc. will post 2.28 EPS for the current fiscal year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 26,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $44.70, for a total transaction of $1,162,200.00. Following the completion of the transaction, the insider now owns 46,444 shares in the company, valued at $2,076,046.80. This trade represents a 35.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $46.96, for a total value of $3,687,299.20. Following the transaction, the chief executive officer now owns 435,208 shares of the company’s stock, valued at $20,437,367.68. This represents a 15.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 209,863 shares of company stock worth $9,689,847 in the last quarter. 5.40% of the stock is owned by corporate insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.